about
Genetics of primary bilateral macronodular adrenal hyperplasia: a model for early diagnosis of Cushing's syndrome?Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation.Evaluation of a standardized protocol for processing adrenal tumor samples: preparation for a European adrenal tumor bank.Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation.Leukemia inhibitory factor as an intrapituitary regulator of pro-opiomelanocortin gene expression and corticotrope ontogeny.Extended treatment of Cushing's disease with pasireotide: results from a 2-year, Phase II study.Chronic growth hormone (GH) hypersecretion induces reciprocal and reversible changes in mRNA levels from hypothalamic GH-releasing hormone and somatostatin neurons in the rat.Loss-of-function mutations in the CABLES1 gene are a novel cause of Cushing's diseaseIGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma.Clinical characterization of familial isolated pituitary adenomas.Frequent phosphodiesterase 11A gene (PDE11A) defects in patients with Carney complex (CNC) caused by PRKAR1A mutations: PDE11A may contribute to adrenal and testicular tumors in CNC as a modifier of the phenotype.Phosphodiesterase 11A (PDE11A) genetic variants may increase susceptibility to prostatic cancer.Role of the PKA-regulated transcription factor CREB in development and tumorigenesis of endocrine tissues.Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.Aberrant receptor-mediated Cushing's syndrome.Phosphodiesterase 11A (PDE11A) and genetic predisposition to adrenocortical tumorsUrine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumorsCombined transcriptome studies identify AFF3 as a mediator of the oncogenic effects of β-catenin in adrenocortical carcinoma.The ARMC5 gene shows extensive genetic variance in primary macronodular adrenocortical hyperplasia.New insights in the genetics of adrenocortical tumors, pheochromocytomas and paragangliomas.Adrenal pathophysiology: lessons from the Carney complex.Functional Characterization of PRKAR1A Mutations Reveals a Unique Molecular Mechanism Causing Acrodysostosis but Multiple Mechanisms Causing Carney Complex.Aberrant DNA hypermethylation of SDHC: a novel mechanism of tumor development in Carney triad.Comparison of the effects of PRKAR1A and PRKAR2B depletion on signaling pathways, cell growth, and cell cycle control of adrenocortical cellsConstitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome.Systematic screening for PRKAR1A gene rearrangement in Carney complex: identification and functional characterization of a new in-frame deletionMechanisms of disease: adrenocortical tumors--molecular advances and clinical perspectives.SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples.Insights into the molecular biology of adrenocortical tumors.Phosphodiesterase 11A expression in the adrenal cortex, primary pigmented nodular adrenocortical disease, and other corticotropin-independent lesions.PKA regulatory subunit 1A inactivating mutation induces serotonin signaling in primary pigmented nodular adrenal disease.Functional phosphodiesterase 11A mutations may modify the risk of familial and bilateral testicular germ cell tumors.Exploration and management of adrenal incidentalomas. French Society of Endocrinology Consensus.French consensus on the management of acromegaly.Carney complex: Clinical and genetic 2010 update.Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments.The Weiss score and beyond--histopathology for adrenocortical carcinoma.Protein kinase A alterations in endocrine tumors.Laparoscopic adrenalectomy for adrenocortical carcinoma: a medico-surgical perspective.Management of hyperglycaemia in Cushing's disease: experts' proposals on the use of pasireotide.
P50
Q26799128-D75DC489-8FB4-4FDE-8120-4D0F118D5A6CQ28253227-2CB445A4-DD41-4D02-B5AC-57E0F5AC8D91Q30877239-60BFDFA9-57E5-4205-8C98-0699F31F39E6Q33682397-997AC553-BE8C-4843-A4D4-5FD47D71051AQ33726848-80E9C785-A19F-41C8-B5D5-96668ACB88F4Q33858344-942FCC07-8CE6-4312-AB23-D02A6D6A6D77Q33897071-61FBDFBB-2CD0-474E-AD16-C23DA335CECCQ33904619-D03E978C-589F-4775-B780-2C9E1BC342A8Q33999643-F7009F22-0D19-4E29-81F7-CC888A7F0ECFQ34540360-00F8ACD7-3AD1-433D-BE5A-2E7FB744AE19Q34571810-2EB380C3-14BB-4217-9BC9-0EA349125F95Q34571859-BAA0EA09-0619-4963-99FF-8A825A67E34CQ34741102-A4635C5F-E2E8-41DE-8866-53C198D0CABAQ35012985-24363E9C-15C6-412E-BF17-36AFE5278621Q35085694-9E9FA950-C7D7-4999-90A5-5B27878A16D7Q35100928-EFB8810C-FF7B-40C5-85D7-379313B73387Q35597963-5A22EBC5-C784-4885-A2FB-2E54799602AEQ35905777-59CA3A13-1308-418E-AAEC-C043C251455FQ36066749-85F3CFE4-9B3F-4408-9E91-6EC4DEB6F120Q36185325-21A307FA-E73E-441A-B370-72058195AB6EQ36271643-49849EAC-F1E0-426E-8D6E-DEE0ABF82E60Q36282925-A3C51F02-FF0B-4A18-A56F-3122E04F3447Q36489471-F5AA43C3-FB80-48A1-803A-9D7C10A4FE19Q36503899-0B786FD2-3284-4E0B-BC41-46A4FA7EE6ECQ36503929-180E0776-6F35-4F9E-8242-6A36153A1920Q36522801-4D110B42-E671-4C55-83CB-385A0F06AA8AQ36643559-BDA7F863-D77A-496C-858B-CFF1DCC84220Q36718929-349E5461-7723-404A-9325-75053B62A3F9Q36788107-F576BB2C-864B-4226-BB64-BD369303E6E4Q37267926-D524B5A8-ECFD-419A-8221-E5B105456230Q37277025-5B86A44E-7186-417E-B51F-F23C4038FD44Q37325191-C3E6AF78-D2C3-461C-971E-12C37E660BC4Q37330805-43B6215E-8951-4DA1-8CE4-BBF523870B40Q37433109-75668B95-0709-4211-AB21-34C9539E3B95Q37789987-89E66982-3854-4690-95CF-8D7F9692B6D0Q37826288-0AFCCA95-CDFC-44CE-992B-29CAC5C05C19Q37945487-6D93BE04-3137-4C0B-BAA5-E2D5B5225297Q38023287-EB108407-50CC-40DA-A487-BD505AF9EB0CQ38041783-2F3F87F3-C537-4156-8D19-7699C6245D47Q38066321-E5BC16E1-3422-4357-BE27-5212FAE11F43
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jérome Bertherat
@ast
Jérome Bertherat
@en
Jérome Bertherat
@es
Jérome Bertherat
@nl
type
label
Jérome Bertherat
@ast
Jérome Bertherat
@en
Jérome Bertherat
@es
Jérome Bertherat
@nl
altLabel
Jerome BERTHERAT
@en
prefLabel
Jérome Bertherat
@ast
Jérome Bertherat
@en
Jérome Bertherat
@es
Jérome Bertherat
@nl
P106
P31
P496
0000-0003-2551-3008